Loading
Latest filing published 06 Mar 2023 for Concert Pharmaceuticals, INC.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Jesper Hoeiland (board member) discloses dealings in Concert Pharmaceuticals, Inc. to SEC (Form 4). We count 3 filings; the first trade dates from 10 June 2021 and the latest from 6 March 2023.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
Most recently, on 6 March 2023, the filings show a transaction in Concert Pharmaceuticals, Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations